COMPANY PROFILE

COMPANY BIODATA

Shasun Research Centre (SRC) Contact

Research Centre

No 27, Vandalur – Kelambakkam Road,

Keezhakottaiyur Village,
Chennai 600048,
Tamil Nadu, India.

Tel: 91-44-47406100
Fax: 91-44-47406190
Email: src@shasun.com

Multi Product Facility Cuddalore Contact

Multi Product Facility – Cuddalore

A1/B SIPCOT Industrial Estate,

Kudikadu, Cuddalore – 607 005
Tamil Nadu, India

Tel: +91-4142-239701, 239702, 239703, 239704

Fax: +91-4142-239709
E-mail: shacud@shasun.com

1
ABOUT THE COMPANY
Shasun is one of the fastest growing service organization dedicated to customers in the
global pharmaceutical industry, the company also offers its service for providing contract research
custom synthesis, contract manufacturing and contract formulation to its clients mainly innovator
companies, almost 50% of its revenues are derived from this segment.

SHASUN AT A GLANCE
Incorporated in 1976, Shasun chemical and Drugs Ltd (SCDL) is headquartered in Chennai,
India. It manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric
coating recipients with a significant presence in some key generics. Shasun has created a strong
product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale
production capacities. It has emerged as a key player in various service segments in the
pharmaceutical field besides APIs and intermediaries.

SHASUN DRUG PRODUCTS

Shasun manufactured the bulk drug namely Ranitidine, Niazatidne, Ibuvrofen and
Chlorophesin. It manufactures the drugs for human beings only.
Shasun today is one of the largest producers of Ibuvrofen worldwide. Offering derivatives
of Ibuvrofen such as Ibuvrofen sodium, Ibuvrofen Lysinate and S+ Ibuvrofen. It is also one of the
world’s major producers of Ranitidine and Nizatidine. Interalia it also manufactures Gabapentin
sevelamer, Carisoprodal, Diphendramine, Hydochloride, Cycloserine, Isradipine, HPMCP. It
products are exported to countries across North America, Europe, Asia and Latin, America. Besides
the products mentioned above shasun makes host of other APIs and Intermediates for its customer
on contract basis.
In its Endeavour to become a true one-stop shop for global pharmaceutical companies,
Shasun is evolving its business model to become to complete provider of services, right from the
discovery stage to manufacturing formulations. The company has added finished formulation
capability as forward integration, and has invested in large facility to cater to the regulated
international market.

SHASUN BIO TECHNOLOGY

Shasun recognizes the role of biotechnology as the future of the global pharmaceutical
industry in enhancing the repeatic effectiveness, improving life style quality and strengthening
corporate profitability. In view of this, the company is involved in the creation of significant bio

2
technology capabilities & Capacities in the area or protein processing solutions to provide services
for the bio tech & pharmaceutical companies.

SHASUN CUDDALORE

Established in 1991, the cuddalore facility has been built as a true multipurpose facility. At
this facility, several API’s and excipients have been commercialized over the last few years. Our
superior product quality has helped us establish supply chains with the original innovator
companies such as Glaxe smith Kline and Eli Lilly for products like Ranitidine and Nizatidine.
Innovation and Excellence are key words in shasun, in whatever activity we do.
The newly commissioned formulation facilities with vouchsafe this statement. Just enter
into these techno-savvy facilities some of the latest technologies that the pharmaceutical world has
moved towards. Spread over an area of 100,000 sq. ft., The facilities can handle oral solid dosages
(OOSDs) with an annual production capacity of over 3.0 billion tables concluding Film/sugar
coated) and 120 million capsules (hard gelatin).
Some of the key features of this facility are,
1. Steam less, in situ cast terrazzo flooring for all manufacturing areas
2. Air handling units with terminal mounted EU 13 HEPA filters, to provide class 100,000
environments in the manufacturing areas, continuously monitored and controlled by building
automation system.
3. Vertical material flow in table compression areas, to avoid cross contamination.
4. Bar-code readers for entire manufacturing activity starting form material dispensing till
equipment cleaning.
5. Automatic container cleaning system, ensuring validation of cleaning procedures.
6. 100% metal detection scanning of all products.
7. Access controls and CCTV monitoring of man movement to various areas inside the facility,
to avoid violation of GMP.
8. Phaormacodes on all printed packaging materials.

ORGANIC BLOCK I
Consists of twelve laboratories made for each team where research shall be out by out scientists
and well-trained chemists. It shall also have analytical lab that ensures quality control (QC) of
R&D operations.
The facility includes a training centre, employee recreation centre, fitness centre and a
cofeyeria. The centre at the campus shall be fully integrated with internet and intranet facilities.

3
 The entire complete is covered with 25% of green bolt around it. It shall as a nerve centre
for research and development where activities will include contract research and customs synthesis
along with other innovative collaborative research with academics as well as industries.
Phase 1 activities of modern R&D centre will be followed by phase. 2. Which shall consists
of two more organic chemistry research buildings, auditorium & recreation centre and extensions
of the other existing facilities such as analytical and quality control, stores etc.,
This centre shall strive to achieve excellence in chemistry for manufacture of APIs and
intermediates for the health case industry by complying by with full CGMPS standards and quality.
Shasun is forced on creating and delivering innovative and quality products to help people
lead healthier liver. Shasun research centre shall create an environment for innovation and learning
that foresters, in each one of us at shasun, a desire to excel and willingness to experiment as we
believe “For life-science works”.

4
Administration & quality assurance (QA) Block
The building host the library, project management team, training centre and shall also comprise
Administration area for the centre. This will also host QA team that shall ensure one quality
standards to the highest level.
ANALYTICAL BLOCK
Shall consist of the entire quality control and analytical team with all sophisticated analytical
equipments. This department will cater to all the scientists in the R&D centre.
SCALE UP LAB
Consists of three state to the art kilo labs complying with cGMPs standards to carry out experience
on a relatively bigger scale. This area a class 10,000 area and will have all the provisions for
milling, drying and packing as a part of clean room activities. There will also be a hydrogenation
room separated from the main building area.
RAW MATERIAL STORE
Consists of a state-of the art store facility for all chemicals and caters to the needs of al chemists
and analyst of the R&D centre.
SERVICE & UTILITY BLOCK
Consists of utilities the R&D centre like electrical panel room, D.G. set room, fire hydrant pump
house and mineral water plant.
EFFLUENT TREATMENT PLANT (ETP)
This centre has state of art effluent treatment plant with zero discharge facility adopting highest
environmental standards and most modern technology showing out complete commitment to
environment and the society on the whole.
SHASUN THE PAST
Foundation was built by establishing each its products to the best of its process efficiencies and
quality, which facilitated the innovators to qualify shasun, which propelled the growth to multi-
fold level of production. With its consistent and effective deliverables the company entrenched
itself with these innovators companies and also extended its range of services, beyond its product
capabilities. The company has also envisaged a great business opportunity in the CRAMs business
model and equipped itself for the future.
SHASUN THE PRESENT
Today shasun has emerged as a key player in various services segments in the pharmaceutical field
besides manufacturing and selling of APIs and intermediates. The recent acquisition of the business
of phodia pharma solutions in UK has strengthened its vision to be a leading CRAMS player in the
world. The philosophy is to remain as a reliable manufacturer and service provides for its
international customers rather than competing with them makes shasun stands out in the crowd.

5
With its forward integration into the finished dosage contract manufacturing capabilities. Shasun
enjoys the reputation of an integrated service provider across the value chain.
SHASUN THE FUTURE
The future has a lot in store for shasun. As a part of its global alliances and partnering arrangements,
Shasun will continue to offer its services across the value chain with enhanced capabilities &
Capacities. His would include services from the lab to the API plant ending up with
development/manufacturing of finished dosage. Shasun would be able to offer its customers the
advantages of outsourcing from both western lab /plants in UK and Eastern labs/plans in India and
thus be a preferred partner throughout the life cycle of the drug.
PREPARATION OF FINANCIAL STATEMENTS
In Shasun, the financial statements have been prepared to comply in all materials aspects
with applicable accounting principles in India, the accounting standards as notified by the
companies. Accounting standard rules (2006) the relevant provisions of the companies act, 1956
and guidelines issued by the securities exchange board of India (SEBI). The Accounting principles
have been consistently applied by the company except for the changes in accounting policies
described more fully below with those used in the previous year.
The preparation of financial statements requires management to make estimated and assumptions
that effect the reported amounts revenue and expenses during the period reported. Actual results
could differ from those estimates.
FINANCIAL REVIEW OF SHASUN
Manufacturing cost as a proportion of net revenues increased from 63% in 2009-10 to 73% 2010-
11. The increase is largely on account of reduces sale of one of its key product, besides increase in
raw material and utility costs.Selling expenses remained at 4% of net revenues in 2010-11. Other
operating expenses too remained largely under control.
The operating margin was lower, at 12% as compared to 17% last year, mainly due to reduced sale
of one its key product, higher raw material costs, and the running cost of the formulation facility,
from which commensurate revenue is still to be generated. The company made a depreciation
provision of Rs.265 million in 2010-11 compared to Rs.251 million in 2009-10.The company
provided Rs.28 million for current taxes during 2010-11, an effective tax rate of 11% (5% in 2009-
10). The highest tax rate was on account of minimum alternate tax (MAT) imposed of EOU profit
during the current year.
ACHIEVEMENTS
 ISO 9001:2000, ISO: 14001, OHSAS 18001 AND ISO: 7001.

6
  CGMP- complaint API facilities successfully inspected by US FDA, UK MHRA,
RGA and other regulatory authorities.
 CGMP- complaint finished dosage facility inspected by UK MHRA and US FDA.
 Found safety standard certifications for the UK facilities.
 Shares listed on the Bombay stock exchange and national stock exchange.

DEPARTMENTS OF SHASUN
The various departments of SHASUN are
Departments:-

 Production Department - Manufacture, Reserve, Store term center, register

center.
 Processing Department - Bleaching, Printing and Byeing.
 Engineering Department – Quality, Restful Penal, cable center.
 Warehouse Department – Examining, Packing, and Balling.

7
MILESTONE

ONE PRODUCT ONE MARKET

1976-77

Incorporated in Chennai, India. First production facility (for Analgin)

1986

Second production facility at Pondicherry (for Ibuprofen)

1991

Third manufacturing facility in Cuddalore

(for Ranitidine HCl)

1992

Established US subsidiary

1994

Initial public offering raised approx Rs. 6 Crs

2005

Commissioned new Research Centre and Formulations facility

2006

Successfully completed acquisition of Rhodia Pharma Solutions business.

2009

Commercial launch of recombinant streptokinase in India (June 09)

2010

Finished dosages sales grows 100% and reaches Rs. 50 crores

2011

Formed 50:50 JV Shasun NBI LLC in USA with Nanoparticle Biochem

Major expansion of formulations facility to 5 billion OSD

2012
8
  Milestone turnover of Rs.1000 crores
 Formulation capacity expands to five billion USD

2013

 Awarded the 2012 NEPIC UK Award for innovation

 Silver Award by Pharmaexil for highest export in large scale categor

2014

 Joint Venture company “Alivira Animal Health Ltd”

 Acquisition of global rights of “Nuprin” brand
 Successful completion of US FDA and Brazilian ANVISA inspection
 Successful completion of MHRA EU inspection at SPSL, UK

OUR PRODUCTS & SERVICES

Our continued investment in our people and our facilities means that today, Shasun can
bring together state-of-the-art equipment in India and the UK, proprietary technologies and highly
experienced people who are among the best in the industry, to offer a full range of development
and manufacturing services for intermediates, API and formulations, covering the entire life cycle
of a product at any scale – from grams to tonnes – from pre-clinical to validation and commercial
supply, with all the associated supporting services.

All of these services can be offered from our USFDA, PMDA and MHRA approved sites,
eliminating risk, time and cost associated with technology transfer from one service provider to
another, accelerating ‘right first time’ product development to allow our customers to reach the
market quicker and more cost effectively and ensuring that product supply is never on the critical
path.

9
 OBJECTIVES OF THE STUDY

PRIMARY OBJECTIVE
The primary objective of my study at SHASUN Chemicals to lay down the foundation of

training and development.

 To examine the effectiveness of training in overall development of skills of workforce.

 To examine the impact of training on workers.
 To study the changes in behavioral pattern due to training.
 To find out new methods of training and development at SHASUN.

SECONDARY OBJECTIVE
The objective of my study about employees training and development to improve the current

process of employees training and development at SHASUN Chemicals

 My another objective is to apply my learning in the area of Human Resources so that I

gain significant practical and Understand the nature and importance of training and
development and identify the various inputs that should go into any programme.

 Delineate the different stages in a training and development programme and describe

each step.
 Understand the need for and the ways of training for international assignments.

10
 SCOPE OF THE STUDY

In this project I have tried to present details about the training and development programs being
presently followed in SHASUN and the feedback, I collected from different employees during
my interaction with them.

The scope of training and development can be explained with the help of following points:-

 Exact position of performance of employees through their feedback

 Development of the employees through various training and development

programs.

 Developing altered of unbiased treatment to all employees

 This research provides me with an opportunity to explore in the field of Human

Resources.

 This research also provides the feedback of people involved in the Training and
development process Apart from that it would provide me a great deal of exposure to
interact with the high profile managers of the company.

11
 LIMITATION OF STUDY

 Most of the respondents were reluctant in giving information.

 It was very difficult to connect the trainees and the supervisors, as they were busy
with their regular day to day activities.
 The short period had been given, so the study does not covers the whole.
 Sample Study Size 100.
 During my training period although the management and plant personnel were very
co-operative & extended their full support, yet there were following limitations
associates with my study which I would like to mention: Due to the busy schedule
of an organization I was unable to grasp the precious words of the HRD Manager.
 In view of the limited time available for the study, only the Training and
Development process could be studied.

12
13